Innovative collaboration further expands Sofra platform
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Noxopharm Ltd. reports on a collaboration with InhaTarget Therapeutics to expand its Sofra technology platform, focusing on innovative treatments for lung diseases. The filing highlights the first results from a study demonstrating the versatility of Sofra's novel lung delivery method and its anti-inflammatory properties. InhaTarget's proprietary lipid nanoparticles were used to successfully encapsulate Noxopharm's oligonucleotides, achieving significant reductions in lung inflammation in animal models.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Noxopharm
- March 2026 Quarterly Activities Report and Appendix 4C
- Positive SOF-SKN dosing data shows prolonged skin retention
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Resignation of Chief Executive Officer
- Appendix 4D and FY2026 Half Year Financial Report
Later from Noxopharm
- New data shows SOF-SKN active ingredient efficacy
- Noxopharm progresses US regulatory strategy
- Noxopharms Sofra assets to be presented at global conference
- New data confirms cancer-fighting potential
- SOF-SKN manufacturing begins to ensure clinical trial readi
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm